title: Immunotherapeutic strategies in antiphospholipid syndrome.
abstract: Antiphospholipid syndrome is an autoimmune condition, characterised by the persistent presence of antiphospholipid antibodies and either thrombosis or obstetric morbidity. The cornerstone of therapy is long-term anticoagulation to reduce morbidity and mortality; however, better understanding of the immunological pathways may direct us to develop future therapeutic strategies. We provide an overview of the current understanding of the immunopathogenesis of this perplexing condition and its associated morbidities and current evidence for some of the immunotherapeutic strategies.
authors: Department of Rheumatology, Austin Health, Melbourne, Victoria, Australia.|Department of Rheumatology, Monash Health, Melbourne, Victoria, Australia.|School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia.
authors: A Y
authors: AY
authors: Hoi
authors: Department of Rheumatology, Austin Health, Melbourne, Victoria, Australia.
authors: L
authors: L
authors: Ross
authors: Department of Rheumatology, Austin Health, Melbourne, Victoria, Australia.
authors: J
authors: J
authors: Day
authors: Department of Rheumatology, Austin Health, Melbourne, Victoria, Australia.
authors: R R C
authors: RR
authors: Buchanan
mesh_terms: D017152:Antibodies, Antiphospholipid / Q000187:drug effects* / Q000276:immunology; D000925:Anticoagulants / Q000627:therapeutic use*; D016736:Antiphospholipid Syndrome / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods / Q000639:trends*; D058990:Molecular Targeted Therapy / Q000639:trends*; D013927:Thrombosis / Q000517:prevention & control*
chemical_list: D017152:Antibodies, Antiphospholipid; D000925:Anticoagulants
keywords: 
  CAPS
  ; antiphospholipid syndrome; therapeutic options